Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma

ZHU Ping; LU Xiya; TIAN Yanfei

doi:10.6039/j.issn.1001-0408.2025.22.14

您当前的位置：

首页 >

文章列表页 >

Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma

更新时间：2025-11-25

- Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma
- ZHONGGUO YAOFANG Vol. 36, Issue 22, Pages: 2833-2837(2025)
- 作者机构：
  
  辽宁省肿瘤医院内镜科，沈阳　110042
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.22.14
  CLC： R735.7;R969.4
- Received：29 May 2025，
  
  Revised：2025-09-22，
  
  Accepted：22 September 2025，
  
  Published：30 November 2025
- 稿件说明：
移动端阅览
祝平,卢西雅,田艳飞.HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察 ^Δ[J].中国药房,2025,36(22):2833-2837.

ZHU Ping,LU Xiya,TIAN Yanfei.Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2025,36(22):2833-2837.
祝平,卢西雅,田艳飞.HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察 ^Δ[J].中国药房,2025,36(22):2833-2837. DOI： 10.6039/j.issn.1001-0408.2025.22.14.

ZHU Ping,LU Xiya,TIAN Yanfei.Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2025,36(22):2833-2837. DOI： 10.6039/j.issn.1001-0408.2025.22.14.

摘要

目的

探讨基于奥沙利铂和氟尿嘧啶药物组合的肝动脉灌注化疗（即HAIC-FOLFOX）联合卡瑞利珠单抗用于不可切除肝细胞癌（HCC）的有效性和安全性。

方法

回顾性收集2021年1月1日－2023年3月1日于辽宁省肿瘤医院住院治疗的222例不可切除HCC患者的资料，根据治疗方案的不同将其分为对照组（HAIC-FOLFOX联合索拉非尼，117例）和观察组（HAIC-FOLFOX联合卡瑞利珠单抗，105例）。比较两组患者治疗4个周期后的近期疗效指标[客观缓解率（ORR）和疾病控制率（DCR）

]

和远期疗效指标[中位总生存期（mOS）和1年内中位无进展生存期（mPFS）

]

，治疗前及治疗4个周期后的肿瘤标志物（甲胎蛋白、癌胚抗原、糖类抗原19-9）、免疫功能指标（CD3

、CD4

和CD8

T细胞亚群）水平，以及治疗期间的不良反应发生情况。

结果

观察组患者的ORR为55.24%，显著高于对照组的35.90%（

＜0.05），而两组患者的DCR比较差异无统计学意义（

＞0.05）；观察组患者的mOS、1年内mPFS（15.22、10.83个月）均显著长于对照组（11.34、8.04个月）（

＜0.05）。治疗4个周期后，两组患者的肿瘤标志物水平均显著低于同组治疗前，观察组患者的CD3

、CD4

T细胞比例均显著高于同组治疗前（

＜0.05）；且观察组患者的上述指标均显著优于同期对照组（

＜0.05）。观察组发生1～3级免疫相关性肺炎、毛细管增生的患者比例均显著高于对照组（

＜0.05），而两组发生1～3级发热、乏力、皮疹等不良反应的患者比例比较，差异均无统计学意义（

＞0.05）。

结论

相较于HAIC-FOLFOX联合索拉非尼，HAIC-FOLFOX联合卡瑞利珠单抗可显著提高不可切除HCC患者的ORR，延长mOS和1年内mPFS，有效降低肿瘤标志物水平，改善部分免疫功能指标，但会增加免疫相关不良事件的发生风险。

Abstract

OBJECTIVE

To investigate the efficacy and safety of hepatic arterial infusion chemotherapy based on the oxaliplatin and fluorouracil drug combination （HAIC-FOLFOX） combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma （HCC）.

METHODS

The data of 222 unresectable HCC patients hospitalized at Liaoning Cancer Hospital

Institute from January 1， 2021 to March 1， 2023 were retrospectively collected. Based on treatment regimens， patients we

re divided into a control group （HAIC-FOLFOX+sorafenib，

＝117） and an observation group （HAIC-FOLFOX+camrelizumab，

＝105）. Short-term efficacy indicators [objective remission rate （ORR） and disease control rate （DCR）

]

and long-term efficacy indicators [median overall survival （mOS） and median progression-free survival （mPFS） within one year

]

after 4 cycles of treatment， the levels of tumor markers （alpha fetoprotein， carcinoembryonic antigen， carbohydrate antigen 19-9）， immune function indicators （CD3

， CD4

， and CD8

T-cell subsets） before treatment and after 4 cycles of treatment， as well as the occurrence of adverse reactions， were compared between two groups.

RESULTS

The ORR of the observation group was 55.24%， which was significantly higher than 35.90% of the control group （

＜0.05）； while there was no statistically significant difference in DCR between the two groups （

P＞

0.05）. The mOS and mPFS within 1 year of the observation group （15.33， 10.83 months） were significantly longer than the control group （11.34， 8.04 months）（

＜0.05）. After 4 cycles of treatment， tumor marker levels of the two groups were significantly lower than before treatment， and the proportions of CD3

and CD4

T cells were significantly higher than before treatment （

＜0.05）. Above indexes of the observation group were significantly better than the control group at the same time （

＜0.05）. The proportions of patients in the observation group who developed grade 1-3 immune-related pneumonia and capillary proliferation were significantly higher than the control group （

＜0.05）， while there were no statistically significant differences in the proportions of patients experiencing grade 1-3 adverse reactions such as fever， fatigue and rash between two groups （

＞0.05）.

CONCLUSIONS

Compared with HAIC-FOLFOX combined with sorafenib， HAIC-FOLFOX combined with camrelizumab can significantly improve the ORR， prolong mOS and mPFS within 1 year， effectively reduce tumor marker levels， and improve certain immune function indicators in patients with unresectable HCC， but it increases the risk of immune-related adverse events.

关键词

Keywords

references

ZHAO M ， GUO Z ， ZOU Y H ， et al . Arterial chemotherapy for hepatocellular carcinoma in China：consensus recommendations [J ] . Hepatol Int ， 2024 ， 18 （ 1 ）： 4 - 31 .

TOH M R ， WONG E Y T ， WONG S H ， et al . Global epidemiology and genetics of hepatocellular carcinoma [J ] . Gastroenterology ， 2023 ， 164 （ 5 ）： 766 - 782 .

ZHU S Q ， YU Y H ， YANG M Q ， et al . Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma：recent advances and literature review [J ] . Expert Rev Anticancer Ther ， 2024 ， 24 （ 6 ）： 423 - 434 .

JIANG P ， CHEN C ， TIAN J ， et al . Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma：a systematic review and meta-analysis [J ] . Acad Radiol ， 2025 ， 32 （ 8 ）： 4595 - 4606 .

ZHANG T Q ， GENG Z J ， ZUO M X ， et al . Camrelizumab（a PD-1 inhibitor）plus apatinib（an VEGFR-2 inhibitor）and hepatic artery infusion chemotherapy for hepatocel-lular carcinoma in Barcelona Clinic Liver Cancer stage C（TRIPLET）：a phase Ⅱ study [J ] . Signal Transduct Target Ther ， 2023 ， 8 （ 1 ）： 413 .

JIANG X M ， WANG P ， SU K ， et al . Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma：a multicenter，retrospective study [J ] . Ann Hepatol ， 2024 ， 30 （ 2 ）： 101578 .

王姗，吴庆旺，李小科，等 . 《原发性肝癌诊疗规范（2019年版）》解读 [J ] . 临床肝胆病杂志， 2020 ， 36 （ 5 ）： 996 - 999 .

SCHWARTZ L H ， LITIÈRE S ， DE VRIES E ， et al . RECIST 1.1：update and clarification：from the RECIST Committee [J ] . Eur J Cancer ， 2016 ， 62 ： 132 - 137 .

ZSCHÄBITZ S ， BIERNATH N ， HILSER T ， et al . Enfortumab vedotin in metastatic urothelial carcinoma：survival and safety in a European multicenter real-world patient cohort [J ] . Eur Urol Open Sci ， 2023 ， 53 ： 31 - 37 .

FU S M ， XU Y K ， MAO Y ， et al . Hepatic arterial infusion chemotherapy，lenvatinib plus programmed cell death protein-1 inhibitors：a promising treatment approach for high-burden hepatocellular carcinoma [J ] . Cancer Med ， 2024 ， 13 （ 9 ）： e7105 .

YI J Z ， ZHU Z J ， LIU G W ， et al . Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure：multicenter，real-world study [J ] . Hepatol Res ， 2024 ， 54 （ 6 ）： 575 - 587 .

QIAO J H ， WANG Y ， FU C X ， et al . Complete response and long-term survival after short-course camrelizumab plus apatinib，hepatic arterial infusion chemotherapy，and transarterial chemoembolization in large and advanced hepatocellular carcinoma：a case report [J ] . J Gastrointest Oncol ， 2024 ， 15 （ 5 ）： 2323 - 2329 .

CHENG A L ， QIN S K ， IKEDA M ， et al . Updated efficacy and safety data from IMbrave150：atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma [J ] . J Hepatol ， 2022 ， 76 （ 4 ）： 862 - 873 .

XIA Y X ， TANG W W ， QIAN X F ， et al . Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma：a single-arm，open label，phase Ⅱ clinical trial [J ] . J Immunother Cancer ， 2022 ， 10 （ 4 ）： e004656 .

BLUM S M ， ROUHANI S J ， SULLIVAN R J . Effects of immune-related adverse events（irAEs）and their treatment on antitumor immune responses [J ] . Immunol Rev ， 2023 ， 318 （ 1 ）： 167 - 178 .

MA R ， WANG J L ， WANG Y Y . Recall of reactive cutaneous capillary endothelial proliferation（RCCEP）induced by stereotactic body radiation therapy（SBRT）in a patient with lung squamous cell carcinoma [J ] . Exp Hematol Oncol ， 2022 ， 11 （ 1 ）： 78 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of tislelizumab in the treatment of advanced non-small cell lung cancer： a meta-analysis

Network meta-analysis of first-line treatment of metastatic colorectal cancer with different chemotherapy combination regimens

Efficacy and safety of luspatercept in the treatment of myelodysplastic syndrome anemia：a single-group rate meta-analysis

Improve effects of aromatase inhibitors on the height of children with short stature

Efficacy and safety of Compound danshen preparations combined with chemical drugs for peptic ulcer： a meta-analysis

Related Author

WANG Yanxue

LIAN Xiaotong

LIANG Ziying

GUO Xinyi

YUAN Qiuyi

WANG Jinni

QIN Yixuan

DING Xiaolian

Related Institution

College of Pharmacy， Guangxi Medical University

Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation

Guangxi Key Laboratory of Bio-targeting Theranostics

Inner Mongolia Clinical Medical College， Inner Mongolia Medical University

Day-care Unit， Inner Mongolia Armed Police Hospital

⁰